Antigen delivery platforms

Abstract

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

1 - 46 . (canceled) 
     
     
         47 . A composition comprising an RNA delivery system and RNA molecules comprising a sequence that encodes a Varicella zoster virus (VZV) glycoprotein gE immunogen. 
     
     
         48 . The composition of  claim 47 , wherein the RNA delivery system is lipid nanoparticles. 
     
     
         49 . The composition of  claim 47 , wherein the RNA delivery system is a cationic nanoemulsion. 
     
     
         50 . The composition of  claim 48 , the lipid nanoparticles comprising a PEGylated lipid, cholesterol, 1, 2-Diastearoyl-sn-glycero-3-phosphocholine (DSPC), and a cationic lipid. 
     
     
         51 . The composition of  claim 47 , the RNA molecules comprising at least one modified nucleotide. 
     
     
         52 . The composition of  claim 51 , the at least one modified nucleotide selected from the group comprising pseudouridine, N6-methyladenosine, 5-methylcytidine, and 5-methyluridine. 
     
     
         53 . The composition of  claim 47 , the RNA molecules further comprising a 3′ poly A tail. 
     
     
         54 . The composition of  claim 47 , the RNA molecules further comprising a 5′ Cap. 
     
     
         55 . The composition of  claim 54 , the 5′ Cap having a Cap 0 structure or a Cap 1 structure. 
     
     
         56 . The composition of  claim 47 , the RNA molecules being self-replicating RNA. 
     
     
         57 . The composition of  claim 50 , the cationic lipid comprising a tertiary amine. 
     
     
         58 . The composition of  claim 48 , the lipid nanoparticles encapsulating at least half of the RNA molecules. 
     
     
         59 . The composition of  claim 48 , the RNA molecules further comprising a 5′ Cap 1 structure and a 3′ poly A tail; and the lipid nanoparticles comprising a PEGylated lipid, cholesterol, DSPC, and a cationic lipid comprising a tertiary amine. 
     
     
         60 . A method of eliciting an immune response in an individual, the method comprising administering to the individual an effective amount of the composition of  claim 47 . 
     
     
         61 . The method of  claim 60  comprising administering two or more doses of the composition. 
     
     
         62 . A method of eliciting an immune response in an individual, the method comprising administering to the individual an effective amount of the composition of  claim 50 . 
     
     
         63 . The method of  claim 62  comprising administering two or more doses of the composition. 
     
     
         64 . A method of eliciting an immune response in an individual, the method comprising administering to the individual an effective amount of the composition of  claim 59 . 
     
     
         65 . The method of  claim 64  comprising administering two or more doses of the composition.